Incorrect password
evipedia.ai Suggest Edit

Dasatinib & Quercetin as a Senolytic Therapy

Evidence Review created on 05/09/2026 using AI4L / Opus 4.7

Also known as: D+Q, Dasatinib plus Quercetin, D&Q Senolytic Cocktail

Motivation

Dasatinib and Quercetin is an intermittent, two-drug combination aimed at clearing senescent cells — cells that have stopped dividing but resist programmed death and secrete inflammatory signals that drive tissue dysfunction. Dasatinib is a prescription cancer drug originally approved for leukemia, while Quercetin is a flavonoid found in many plant foods. Together, they were the first combination shown in preclinical models to selectively eliminate senescent cells, giving rise to a category termed “senolytics.”

The interest in this combination stems from the cellular senescence theory of aging, which proposes that the accumulation of senescent cells with age contributes to chronic inflammation, tissue stiffening, and age-related disease. Animal studies have shown extension of healthspan and improvements in physical function, while early human trials in lung-scarring and kidney-related conditions have demonstrated reductions in senescent-cell markers and tentative functional signals.

This review examines what is currently known about the mechanism, expected benefits, and risks of intermittent dosing as a senolytic strategy, and surveys the state of human clinical evidence as it relates to longevity-oriented adults considering off-label use.

Benefits - Risks - Protocol - Conclusion

This section curates expert long-form content offering high-level overviews of the Dasatinib & Quercetin senolytic combination.

Only three sources meeting the “substantial depth” criterion for the Dasatinib & Quercetin senolytic combination could be identified across the prioritized expert outlets and a broader web search; rather than padding with marginally relevant content, the list is kept to the qualifying items. Peter Attia, Andrew Huberman, and Chris Kresser have not published dedicated long-form content specifically on this combination.

Grokipedia

No dedicated Grokipedia article for the Dasatinib & Quercetin senolytic combination was found.

Examine

No dedicated Examine.com article for the Dasatinib & Quercetin senolytic combination was found. Examine.com does not typically cover prescription medications such as Dasatinib, and while Quercetin has its own page, the senolytic-combination protocol is not addressed there.

ConsumerLab

No dedicated ConsumerLab article for the Dasatinib & Quercetin senolytic combination was found. ConsumerLab does not typically cover prescription medications such as Dasatinib, so the combination protocol is outside its scope.

Systematic Reviews

This section lists systematic reviews and meta-analyses indexed on PubMed that examine senolytics, with attention to those covering the Dasatinib & Quercetin combination.

Mechanism of Action

Cellular senescence is a state in which cells permanently exit the cell cycle but remain metabolically active, often producing a “senescence-associated secretory phenotype” (SASP) — an output of inflammatory cytokines, chemokines, and tissue-remodeling enzymes that can damage neighboring tissue. Senescent cells accumulate with age and at sites of injury, and they resist apoptosis (programmed cell death) by upregulating “senescent cell anti-apoptotic pathways” (SCAPs).

Dasatinib and Quercetin act on complementary SCAPs:

  • Dasatinib is a broad-spectrum tyrosine-kinase inhibitor (a drug that blocks signaling enzymes used by cells to communicate growth and survival signals). It inhibits Src-family kinases and several other tyrosine kinases that senescent adipose progenitors and other cell types depend on to evade apoptosis. Half-life is approximately 3–5 hours, with high tissue distribution but limited central nervous system penetration. Metabolism is primarily hepatic via CYP3A4 (a key liver enzyme that processes many drugs), making interactions with CYP3A4 inhibitors and inducers clinically important. Dasatinib has high oral bioavailability that is reduced by acid-suppressing drugs.

  • Quercetin is a plant flavonoid that targets BCL-2 family proteins (a group of proteins that block the cell-death program) and PI3K/AKT signaling (a survival-signaling pathway), pushing senescent cells past their apoptotic threshold. Oral bioavailability is low (often cited as <5%), with metabolism through glucuronidation and sulfation; the aglycone is largely converted to glycosylated metabolites in circulation.

The two compounds are synergistic in preclinical models: Dasatinib effectively clears senescent human adipose-tissue progenitor cells, while Quercetin is more active against senescent endothelial cells and certain stem cells. Together they cover a broader spectrum of senescent cell types than either alone. The protocol is designed as “hit-and-run” — short, intermittent dosing exploits the days-long timeline for new senescent cells to repopulate, theoretically minimizing chronic exposure while maintaining the senolytic effect.

Competing mechanistic views note that Quercetin’s in-vivo senolytic activity is debated, given its low bioavailability, and some researchers argue that fisetin (a related flavonoid) may be a more potent partner. Others question how much of the observed clinical effect is attributable to Dasatinib alone versus the combination.

Historical Context & Evolution

Dasatinib was originally developed and approved by the U.S. Food and Drug Administration in 2006 as a treatment for chronic myeloid leukemia and Philadelphia-chromosome-positive acute lymphoblastic leukemia. Quercetin has a much longer history as a dietary flavonoid studied for antioxidant, anti-inflammatory, and cardiovascular effects.

The combination’s emergence as a senolytic is recent. In 2015, a team led by James Kirkland and Laura Niedernhofer at the Mayo Clinic and Scripps Research Institute published a landmark paper identifying senolytic compounds through a hypothesis-driven screen of agents predicted to disrupt SCAPs. Dasatinib and Quercetin were the lead hits; the combination cleared senescent cells in cell culture and improved cardiovascular and physical function in aged or progeroid mice. This established the senolytic concept as a translatable therapeutic strategy. Note on conflicts of interest: the Mayo Clinic senolytics group (including Kirkland and Tchkonia) holds patents related to senolytic interventions and has financial interests in their development, which are disclosed in the underlying publications. Most of the human pilot evidence to date originates from this same group, so the body of clinical evidence is dominated by parties with a direct financial interest in the intervention’s adoption.

Subsequent preclinical work showed extended healthspan, improved frailty measures, restored stem-cell function, attenuated osteoporosis, and slowed progression of several aging-related conditions in rodents. The first human pilot study (in idiopathic pulmonary fibrosis — a progressive scarring lung disease, 2019) reported feasibility and modest functional improvements. A 2019 open-label study in diabetic kidney disease reported reductions in senescent-cell markers in tissue.

The evolution of the field continues to be active: larger, blinded trials are now underway, and questions about which senescent cell types are cleared by D+Q in humans, the durability of effects, and the optimal partner compound for Dasatinib remain open. The current evidence base is best characterized as preclinically rich and clinically early — not yet sufficient to call senolytic therapy effective in humans, but no longer purely speculative.

Expected Benefits

A dedicated literature search across PubMed, ClinicalTrials.gov, and major reviews was performed before drafting this section to ensure the benefit profile reflects the published evidence on D+Q.

High 🟩 🟩 🟩

No benefits in humans currently meet the High evidence threshold for the Dasatinib & Quercetin senolytic combination. The strongest evidence remains in animal models, with limited human pilot data.

Medium 🟩 🟩

No benefits currently meet the Medium evidence threshold in humans for this intervention.

Low 🟩

Reduction in Senescent Cell Burden

Open-label pilot studies in patients with diabetic kidney disease and in patients with idiopathic pulmonary fibrosis reported decreases in tissue and circulating markers of senescence (such as p16INK4a (a tumor-suppressor protein that halts cell division and accumulates in senescent cells)-expressing cells in adipose tissue and circulating SASP factors) following short courses of D+Q. The evidence is from small, unblinded studies with surrogate endpoints. The biological signal is consistent across models but has not been confirmed in larger blinded trials.

Magnitude: In the diabetic kidney disease pilot (n=9), adipose-tissue p16-positive cell counts decreased by approximately 30%, and several circulating SASP markers (IL-1α (interleukin-1 alpha, an early pro-inflammatory cytokine), IL-6 (interleukin-6, a cytokine that drives systemic inflammation), MMPs (matrix metalloproteinases, enzymes that break down structural proteins in tissue)) declined.

Improvement in Physical Function in Idiopathic Pulmonary Fibrosis

A small open-label pilot in idiopathic pulmonary fibrosis (a progressive scarring lung disease) reported improvements in 6-minute walk distance, gait speed, and chair stands after a brief D+Q course. The study lacked a control arm, was short, and the endpoint changes are within the range of variability seen in unblinded interventions.

Magnitude: Improvements in 6-minute walk distance averaged ~20–30 meters and gait speed improved on the order of 0.1 m/s in the small pilot.

Speculative 🟨

Improvement in Healthspan and Frailty

In aged and progeroid mice, intermittent D+Q has produced increases in median lifespan, reductions in frailty index, improved cardiovascular function, and improved physical performance. Whether these effects translate to humans is unproven; current human evidence does not yet test lifespan or frailty endpoints. The basis here is mechanistic and animal-model data only.

Improvement in Bone Density and Reduction in Osteoporosis Progression

Mouse studies suggest D+Q can reduce age-related bone loss by clearing senescent osteocytes and osteoblast progenitors. No human data directly test this benefit; the basis is preclinical and mechanistic.

Improvement in Cardiovascular and Vascular Function

Senescent endothelial and vascular cells contribute to arterial stiffness; preclinical D+Q has improved vascular function and reduced atherosclerotic burden in mouse models. Human evidence is limited to indirect signals from pilot studies; the basis is largely mechanistic.

Improvement in Cognitive Function and Reduction in Neurodegenerative Burden

In mouse models of Alzheimer’s-like pathology and tauopathy (a class of neurodegenerative conditions driven by abnormal accumulation of tau protein in the brain), senolytic dosing has reduced senescent-cell markers in the brain and improved cognition. Dasatinib penetrates the central nervous system poorly, raising questions about whether observed effects are central or peripheral. Clinical trials in mild cognitive impairment are ongoing; the basis remains mechanistic and anecdotal in humans.

Benefit-Modifying Factors

  • Age and senescent-cell burden: Senolytic effect should logically scale with the existing burden of senescent cells, which increases with age and with conditions like obesity, diabetes, chemotherapy exposure, and chronic infection. Younger or metabolically healthy individuals may have less to gain.

  • Pre-existing health conditions: Conditions associated with elevated senescent-cell burden — type 2 diabetes, idiopathic pulmonary fibrosis, chronic kidney disease, post-chemotherapy states, osteoarthritis — are the contexts where pilot trials have looked for benefit. In otherwise healthy adults, the benefit signal is unproven.

  • Sex differences: Some preclinical work suggests sex-specific differences in senescent-cell biology and senolytic response (e.g., effects on adipose tissue and bone may differ by sex), but human data are insufficient to characterize sex-based differences in benefit.

  • Baseline biomarkers: Higher baseline circulating SASP markers (IL-6, MMPs, GDF-15 (growth differentiation factor 15, a stress-response cytokine that rises with age and disease burden)) and a higher p16-positive cell fraction in accessible tissues may identify those most likely to respond. Routine clinical assays for these markers are not standardized.

  • Genetic polymorphisms: Variants in CYP3A4 affect Dasatinib metabolism and may alter exposure. Variants in flavonoid-metabolizing enzymes — UGT1A3 (a glucuronidating enzyme that conjugates Quercetin for excretion) and COMT (catechol-O-methyltransferase, an enzyme that methylates polyphenols and catecholamines) — affect Quercetin pharmacokinetics. Their clinical significance for senolytic response is not characterized.

Potential Risks & Side Effects

A dedicated review of Dasatinib’s prescribing information, FDA (U.S. Food and Drug Administration) labeling, and the published safety data from D+Q pilot trials and oncology experience with Dasatinib was performed before drafting this section.

High 🟥 🟥 🟥

Pleural Effusion

Dasatinib is well known in oncology to cause pleural effusion (fluid accumulation around the lungs), occurring in roughly 10–35% of chronic-myeloid-leukemia patients on continuous dosing, with higher rates at higher doses. The mechanism is thought to involve off-target inhibition of platelet-derived growth factor receptor signaling. Risk under intermittent senolytic dosing is presumed lower because of the brief exposure, but is not zero. Older adults and those with prior cardiopulmonary disease are at higher risk.

Magnitude: ~10–35% in continuous chronic-myeloid-leukemia dosing; expected to be substantially lower with intermittent senolytic regimens, but absolute incidence in senolytic dosing is not yet defined.

Myelosuppression

Continuous Dasatinib use causes neutropenia (low neutrophil counts, increasing infection risk), thrombocytopenia (low platelet counts, increasing bleeding risk), and anemia (low red-cell counts, causing fatigue) in a substantial fraction of leukemia patients. Intermittent senolytic dosing produces less suppression in pilot trials, but transient drops in blood counts have been observed. The mechanism is bone-marrow toxicity from kinase inhibition.

Magnitude: Grade 3–4 myelosuppression in 20–40% of continuous oncology dosing; far lower with brief senolytic regimens, with most pilots reporting no grade 3–4 events.

Medium 🟥 🟥

Bleeding Events

Dasatinib inhibits platelet function via Src-kinase pathways, which can prolong bleeding time and elevate bleeding risk independent of platelet counts. This is clinically relevant for those on antiplatelet or anticoagulant therapy. The effect is dose- and duration-dependent and largely reversible after discontinuation.

Magnitude: Clinically significant bleeding occurs in a few percent of continuous-dosing patients; intermittent senolytic dosing risk is presumed lower but specific incidence figures from senolytic trials are limited.

QT Interval Prolongation

Dasatinib can prolong the QT interval (a measure of cardiac electrical recovery) on electrocardiogram; this may predispose to dangerous arrhythmias when combined with other QT-prolonging drugs or in those with congenital long QT syndrome.

Magnitude: Mean QTc prolongation of approximately 4–6 ms in oncology populations; clinically significant prolongation is uncommon at standard doses.

Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (high blood pressure in the lung arteries) has been reported with chronic Dasatinib use in oncology and is partially reversible on discontinuation. Whether intermittent senolytic dosing carries any risk is not established but is biologically plausible.

Magnitude: Estimated incidence ~0.5–5% in chronic oncology use; expected to be lower with intermittent dosing but not characterized.

Gastrointestinal Side Effects

Nausea, diarrhea, and abdominal discomfort are common with Dasatinib and can also occur with high-dose Quercetin. They are typically mild and self-limited under intermittent senolytic regimens.

Magnitude: Mild gastrointestinal symptoms reported in ~10–20% of pilot-trial participants; severe events rare.

Low 🟥

Drug-Drug Interactions

Dasatinib is a CYP3A4 substrate; potent CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, grapefruit juice) raise exposure and toxicity risk, while CYP3A4 inducers (e.g., rifampin, St. John’s wort) reduce exposure. Acid-suppressing drugs reduce Dasatinib absorption substantially. These interactions are well documented in oncology but have less data in senolytic contexts.

Magnitude: Strong inhibitors can increase Dasatinib AUC (area under the curve, a measure of total drug exposure over time) several-fold; strong inducers can reduce AUC by ~80%.

Renal Effects from High-Dose Quercetin

Very high doses of intravenous Quercetin in past oncology trials caused renal toxicity. Oral Quercetin at the doses used in senolytic protocols has not been associated with significant renal events, but caution is warranted in those with pre-existing kidney disease.

Magnitude: Not quantified in available studies.

Speculative 🟨

Long-Term Off-Target Effects on Stem Cell Compartments

Senolytics may, in theory, affect non-senescent cells with similar survival pathways, including some stem-cell compartments. The clinical significance over years of intermittent dosing is unknown; the basis is mechanistic concern rather than demonstrated harm.

Loss of Beneficial Senescence

A subset of senescent cells contribute to wound healing, tumor suppression, and immune surveillance. Indiscriminate clearance could plausibly impair these functions; this is a theoretical concern raised in the senolytics literature without confirmed clinical evidence.

Risk-Modifying Factors

  • Age: Older adults (especially over 75) face higher baseline risks of pleural effusion and bleeding, and may be more vulnerable to Dasatinib-related adverse events even under intermittent dosing.

  • Pre-existing cardiopulmonary disease: Heart failure, prior pleural disease, or pulmonary hypertension elevate risk for Dasatinib-related pulmonary and cardiac events.

  • Chronic kidney disease: Increases sensitivity to Dasatinib-related fluid retention and may increase susceptibility to high-dose Quercetin’s renal effects.

  • Sex differences: Higher rates of Dasatinib-related pleural effusion have been reported in some series in women; data are limited.

  • Genetic polymorphisms: CYP3A4 poor or rapid metabolizers may have altered Dasatinib exposure. Polymorphisms in the drug transporter ABCB1 (a membrane pump that exports many drugs from cells) may also affect tissue distribution.

  • Baseline biomarkers: Low baseline platelet count, low neutrophil count, abnormal liver function, prolonged QT interval, or low serum albumin all warrant caution.

  • Concomitant medications: Antiplatelet drugs, anticoagulants, QT-prolonging medications, and CYP3A4 modulators substantially modify risk.

Key Interactions & Contraindications

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, clarithromycin, grapefruit juice): Caution. Substantially increase Dasatinib exposure and toxicity. Avoid co-administration; if unavoidable, dose reduction is warranted.

  • Strong CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine, St. John’s wort): Caution. Reduce Dasatinib exposure and may render the dose ineffective.

  • Proton pump inhibitors and H2 blockers (e.g., omeprazole, esomeprazole, ranitidine): Caution. Markedly reduce Dasatinib absorption; separating doses or temporarily holding acid-suppressing drugs is advised.

  • Antacids (e.g., calcium carbonate, magnesium hydroxide): Caution. Reduce Dasatinib absorption when taken concurrently; separate by at least 2 hours.

  • Antiplatelet drugs (e.g., aspirin, clopidogrel, ticagrelor): Caution. Additive bleeding risk via platelet dysfunction.

  • Anticoagulants (e.g., warfarin, apixaban, rivaroxaban, dabigatran): Caution. Additive bleeding risk and potential for unrecognized platelet dysfunction.

  • QT-prolonging drugs (e.g., amiodarone, sotalol, certain antibiotics like azithromycin and levofloxacin, ondansetron): Caution. Additive QT prolongation; ECG (electrocardiogram, a recording of the heart’s electrical activity) and electrolyte review recommended.

  • Other tyrosine-kinase inhibitors: Absolute contraindication for concurrent senolytic use; additive toxicity.

  • Other senolytic agents (e.g., Fisetin, Navitoclax): Caution. Combination data are limited; theoretical risk of additive marrow or immune effects.

  • Quercetin-containing supplements and dietary excess: Additive effect with the Quercetin component; high baseline intake may unpredictably alter the senolytic dose effect.

  • Bromelain and high-dose Vitamin C: May increase Quercetin absorption; this can be intentional but alters effective dose.

  • Populations who should avoid this intervention:

    • Active cancer (other than the specific oncology indications for which Dasatinib is approved)
    • Uncontrolled or severe cardiopulmonary disease (NYHA (New York Heart Association functional classification) Class III–IV heart failure, severe pulmonary hypertension)
    • Severe hepatic impairment (Child-Pugh Class C)
    • Severe thrombocytopenia (<50,000/µL) or active bleeding
    • Recent major surgery (<30 days) or active anticoagulation that cannot be paused
    • Pregnancy or breastfeeding
    • Concurrent strong CYP3A4 modulators that cannot be discontinued
    • Long QT syndrome (congenital) or QTc >500 ms
    • Recent myocardial infarction (<90 days) or unstable cardiovascular disease

Risk Mitigation Strategies

  • Baseline screening before any cycle: Includes complete blood count, comprehensive metabolic panel, liver function tests, ECG with QTc measurement, and a medication review for CYP3A4 modulators, acid suppressors, and QT-prolonging agents — this mitigates the risks of myelosuppression, bleeding, drug interaction-related toxicity, and arrhythmia.

  • Use of intermittent “hit-and-run” dosing rather than continuous dosing: Standard senolytic protocols use a 1–3 day window per cycle and cycles spaced months apart, dramatically reducing cumulative exposure compared to oncology dosing — this mitigates pleural effusion, myelosuppression, and pulmonary hypertension risk.

  • Hold acid-suppressing medications around dosing days: Because proton pump inhibitors and H2 blockers reduce Dasatinib absorption substantially, clinicians often pause them for the dosing days (typically 24–48 hours before through the dosing window) — this mitigates underdosing and inconsistent exposure.

  • Avoid grapefruit and grapefruit juice for at least 72 hours before through 72 hours after dosing: Grapefruit is a strong CYP3A4 inhibitor and can substantially raise Dasatinib levels — this mitigates Dasatinib toxicity.

  • Pause antiplatelet and anticoagulant therapy where clinically safe, in coordination with the prescribing clinician: The standard window is 24–48 hours before through 48 hours after dosing — this mitigates bleeding risk from Dasatinib’s platelet-inhibitory effect.

  • Post-dose follow-up labs: A complete blood count and comprehensive metabolic panel within 1–2 weeks after the cycle, with prompt evaluation of any new dyspnea, edema, or bleeding — this mitigates undetected myelosuppression, fluid retention, and bleeding events.

  • Stop and seek evaluation for new dyspnea, chest pain, leg swelling, or unexplained bleeding: Pleural effusion, pulmonary hypertension, and bleeding can present subtly; early evaluation reduces severity — this mitigates progression of pulmonary and bleeding adverse events.

  • Use only pharmaceutical-grade Dasatinib obtained through a licensed pharmacy: Avoids counterfeit product and dose inaccuracy — this mitigates inadvertent overdose and contamination-related harm.

  • Standardize Quercetin source and form: Use a defined formulation (e.g., quercetin phytosome or pure dihydrate) at trial-equivalent dose, since absorption varies several-fold between formulations — this mitigates variable exposure and unpredictable outcomes.

Therapeutic Protocol

A standard “hit-and-run” intermittent protocol is described below, modeled on the dosing regimen used in the published pilot trials by the Mayo Clinic group (Hickson et al. 2019 in diabetic kidney disease; Justice et al. 2019 in idiopathic pulmonary fibrosis). The protocol is off-label outside specific clinical trial contexts; it is presented for informational purposes only.

  • Standard pilot-trial dose: Dasatinib 100 mg orally once daily plus Quercetin 1000 mg orally once daily, taken concurrently for 3 consecutive days, repeated approximately monthly or quarterly depending on the protocol variant. This is the regimen used in the Hickson et al. 2019 diabetic kidney disease pilot.

  • Lower-dose variant: Some practitioners and a subset of trial protocols use Dasatinib 50 mg with Quercetin 500–1000 mg over 1–2 days, especially in older or more frail individuals.

  • Cycling cadence: Typical cadences in trials range from once monthly to once every 3–6 months. The biological rationale is that senescent cells take weeks to months to repopulate; very frequent dosing is unlikely to add benefit and increases cumulative exposure risk.

  • Best time of day: Dasatinib is typically taken in the morning, with or without food, but consistently relative to acid-suppressing medications. Consistency of timing across the dosing days is more important than time of day.

  • Half-life and dosing frequency for Dasatinib: Approximately 3–5 hours, but the senolytic effect is thought to require only brief exposure to trigger apoptosis in primed senescent cells, supporting once-daily dosing during the cycle.

  • Half-life and dosing frequency for Quercetin: The aglycone has a half-life of 1–2 hours; major metabolites circulate longer (~11–28 hours), supporting once-daily dosing during the cycle.

  • Single dose vs. split dose: The published protocols use single daily doses for both compounds. Split dosing has not been systematically studied in the senolytic context.

  • Genetic polymorphism considerations: CYP3A4 poor metabolizers may have higher Dasatinib exposure and may require dose reduction; rapid metabolizers may have reduced exposure. Pharmacogenetic testing is not standard practice in senolytic protocols. UGT1A3 and COMT variants influence Quercetin metabolism but have no standardized dose adjustment.

  • Sex-based differences: No sex-specific dose adjustments are established in senolytic protocols, although women may have higher rates of certain Dasatinib adverse events.

  • Age considerations: Older adults (especially over 75) often start at the lower-dose variant due to higher adverse-event risk, though the trial-tested dose has been used in older populations. There are no established adjustments at the upper age range; clinicians typically prefer the lower-dose variant.

  • Baseline biomarker considerations: Lower baseline platelet counts (<150,000/µL), lower neutrophil counts (<1,500/µL), or borderline QT prolongation favor the lower-dose variant or deferral until baseline normalizes.

  • Pre-existing health conditions: Stable kidney disease, well-controlled diabetes, and stable mild cardiopulmonary disease have been included in trial populations; uncontrolled or severe disease typically defers dosing.

  • Competing therapeutic approaches: Some practitioners advocate for Fisetin monotherapy (a related flavonoid) instead of D+Q, citing better preclinical breadth and fewer drug-related risks. Others use Quercetin alone in older adults where Dasatinib risks dominate. There is no consensus default among integrative-medicine practitioners; the original Mayo Clinic group’s D+Q regimen remains the most-cited reference protocol.

Discontinuation & Cycling

  • Lifelong vs. short-term: The intervention is, by design, intermittent rather than continuous. There is no evidence supporting indefinite quarterly dosing, and no evidence against it; trials to date have used a fixed number of cycles only.

  • Withdrawal effects: None expected. Senolytic dosing is not associated with withdrawal symptoms in pilot trials; discontinuation is expected to be uneventful.

  • Tapering: Not applicable. The protocol is already pulsed; stopping simply means not initiating the next cycle.

  • Cycling for efficacy: The protocol is itself a cycling regimen. Whether prolonged repetition over years sustains benefit, attenuates due to receptor or pathway changes, or accumulates risk is not characterized in published human data.

  • Reasons to discontinue between cycles: New cardiopulmonary symptoms, unexplained bleeding, abnormal blood counts on follow-up, new diagnoses requiring CYP3A4 modulators or anticoagulation, pregnancy, or onset of malignancy unrelated to the primary indication.

Sourcing and Quality

  • Dasatinib sourcing: Dasatinib is a prescription medication sold under the brand name Sprycel and as authorized generics. It must be obtained through a licensed pharmacy with a valid prescription. Compounded versions are sometimes used, particularly outside oncology indications; provenance and potency assays are essential. Counterfeit Dasatinib has been identified in international markets, making licensed-pharmacy sourcing important.

  • Quercetin form considerations: Quercetin is available as a dietary supplement in several forms — quercetin dihydrate, quercetin aglycone, and phytosome formulations (e.g., complexed with phospholipids), with bioavailability differing several-fold between forms. Trial protocols have generally used Quercetin dihydrate. Phytosome forms (e.g., Quercetin Phytosome) may achieve higher plasma concentrations at lower oral doses; dose-equivalence calculations are not standardized.

  • Third-party testing for Quercetin: Look for Quercetin supplements with third-party testing (e.g., USP, NSF, ConsumerLab certifications) verifying identity and absence of contaminants.

  • Reputable Quercetin brands: Brands frequently cited in functional-medicine practice include Thorne, Pure Encapsulations, Life Extension, Designs for Health, and Jarrow Formulas; the field is broad and changes over time.

  • Avoid combination “senolytic stacks” of unverified composition: Some marketed “senolytic” products combine flavonoids in undefined ratios; without third-party verification of dose, they may not deliver the trial-tested Quercetin amount.

  • Storage: Both compounds should be stored according to their packaging — typically room temperature, away from light and humidity.

Practical Considerations

  • Time to effect: In published pilot trials, biomarker changes (reductions in senescent-cell burden, SASP factors) were measured 11 days to 8 weeks after a 3-day course. Functional improvements in idiopathic pulmonary fibrosis were measured 1 week after the course. Long-term clinical effects have not been demonstrated in humans.

  • Common pitfalls: Underdosing through unrecognized acid-suppressing drug use; inconsistent Quercetin formulation leading to variable absorption; failure to screen for contraindications such as borderline QT prolongation or acute infection; over-frequent cycling without clinical justification; using non-pharmaceutical-grade Dasatinib; ignoring drug interactions.

  • Regulatory status: Dasatinib is FDA-approved only for specific leukemia indications; senolytic use is off-label. Quercetin is sold as a dietary supplement and is not FDA-approved for any disease claim. The combination is not approved for any indication; use outside a registered clinical trial is informal.

  • Cost and accessibility: Generic Dasatinib has reduced costs substantially since patent expiration in some jurisdictions; the 100 mg dose for 3 days remains a meaningful out-of-pocket expense in many markets without oncology insurance coverage. Quercetin is inexpensive. Access barriers are primarily on the prescription side, requiring a willing prescribing clinician.

Interaction with Foundational Habits

  • Sleep: No direct interaction established. Some users report transient fatigue during dosing days, which can affect sleep timing rather than quality. Direction of interaction: minor, indirect; mechanism unclear.

  • Nutrition: Grapefruit and grapefruit juice strongly inhibit CYP3A4 and should be avoided around dosing days, as they increase Dasatinib exposure and toxicity. Quercetin absorption is increased by dietary fat and by co-ingestion with bromelain or Vitamin C; this can be intentional. High-Quercetin foods (onions, capers, apples) ingested in large amounts may modify the effective Quercetin dose. Direction: potentiating for Quercetin absorption with fat or bromelain; potentiating for Dasatinib toxicity with grapefruit (to be avoided). Specific practical considerations: avoid grapefruit and limit excessive Quercetin-rich foods during the dosing window.

  • Exercise: Some preclinical data suggest senolytics may improve exercise capacity and recovery in aged animals. Whether D+Q blunts or potentiates exercise adaptations in humans is not established. Strenuous exercise during dosing days has not been studied; some practitioners advise reducing intensity for 24–48 hours around dosing. Direction: possibly potentiating for chronic adaptations; unclear acute effects. Specific practical considerations: avoid maximal exertion during dosing days as a precaution against bleeding events.

  • Stress management: No direct mechanism linking D+Q to cortisol or stress response. Indirectly, reduced systemic inflammation from senescent-cell clearance could plausibly modulate stress-response biomarkers, but human data are absent. Direction: indirect at most; mechanism speculative. Specific practical considerations: none established.

Monitoring Protocol & Defining Success

Baseline testing before initiating any senolytic cycle establishes safety and provides a reference for post-cycle change. Ongoing monitoring focuses on detecting adverse events early and tracking the limited set of biomarkers that reflect senescent-cell burden.

Ongoing monitoring cadence: complete blood count and comprehensive metabolic panel at 1–2 weeks after each cycle; ECG repeated annually or sooner if QT-prolonging medications are added; senescence biomarkers (where used) at 6–12 weeks after cycles, and functional measures (gait speed, grip strength) every 6–12 months.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
CBC Platelets >150,000/µL, neutrophils >1,500/µL, hemoglobin within sex-specific norms Detects Dasatinib-related myelosuppression and bleeding risk CBC = complete blood count. Pre-cycle and 1–2 weeks post-cycle; conventional reference range allows lower neutrophil and platelet counts
CMP Creatinine, electrolytes, liver enzymes within normal range Detects renal effects, electrolyte imbalances, hepatic stress CMP = comprehensive metabolic panel. Pre-cycle and 1–2 weeks post-cycle
ALT <25 U/L (men), <19 U/L (women) Detects hepatic stress from Dasatinib metabolism ALT = alanine aminotransferase. Functional ranges are tighter than conventional reference (often <40–55 U/L); fasting not required
Electrocardiogram (QTc) QTc <440 ms (men), <460 ms (women) Detects baseline and treatment-emergent QT prolongation Pre-first-cycle and yearly; sooner if new QT-prolonging medication is added
hs-CRP <1.0 mg/L Reflects systemic inflammation, which can be influenced by senescent-cell burden hs-CRP = high-sensitivity C-reactive protein. Avoid during acute infection; conventional reference <3.0 mg/L
IL-6 <2.0 pg/mL A SASP component; declines have been reported after senolytic cycles in pilot work IL-6 = interleukin-6. Functional ranges based on observational longevity studies; assay-dependent
MMP-2/9 Within assay reference SASP markers reflecting tissue remodeling and senescent-cell secretion MMP-2/9 = matrix metalloproteinase-2 and -9. Limited assay availability in routine practice
GDF-15 Lower is generally better; <1,200 pg/mL in older adults is commonly cited Rises with age and age-related disease burden, includes a senescence-associated component GDF-15 = growth differentiation factor 15. Functional ranges from longitudinal aging cohorts
T-cell p16 Lower is generally better A research biomarker of cellular senescence burden T-cell p16 = p16INK4a expression measured in T lymphocytes. Available in research and select specialty labs
Coagulation panel (PT/INR, aPTT) Within normal range Detects bleeding-risk modifiers, particularly in those on anticoagulants PT/INR (prothrombin time / international normalized ratio, a measure of clotting via the extrinsic pathway) and aPTT (activated partial thromboplastin time, a measure of clotting via the intrinsic pathway). Pre-cycle for those on anticoagulant or antiplatelet therapy
  • Qualitative markers:
    • Energy and vitality changes after a cycle
    • Subjective changes in skin, joint, and recovery quality
    • Cognitive clarity and sleep changes
    • Any new dyspnea, edema, bruising, or bleeding (warrants evaluation)
    • Exercise capacity and recovery time

Emerging Research

  • Ongoing trial — Alzheimer’s Disease Senolytics (SToMP-AD Phase II): NCT04685590 — Phase II randomized, double-blind, placebo-controlled trial evaluating intermittent Dasatinib & Quercetin in adults with amnestic mild cognitive impairment or early-stage Alzheimer’s disease who are tau-PET positive; safety, feasibility, and biomarker endpoints; estimated enrollment 48.

  • Ongoing trial — Diabetic Kidney Disease (extended): NCT02848131 — Mayo Clinic Phase II follow-on to the Hickson et al., 2019 pilot, examining senescent-cell burden, frailty index, mesenchymal stem-cell function, and kidney function in additional cohorts with diabetic chronic kidney disease.

  • Completed trial — Alzheimer’s Disease Senolytics (SToMP-AD pilot): NCT04063124 — Phase 1/2 open-label proof-of-concept (n=5) measuring brain penetrance of Dasatinib & Quercetin via cerebrospinal-fluid sampling in older adults with early Alzheimer’s; results posted in 2023 informed the larger Phase II.

  • Completed trial — Idiopathic Pulmonary Fibrosis (Wake Forest pilot): NCT02874989 — Phase 1 single-blind pilot of intermittent Dasatinib (100 mg/d) + Quercetin (1250 mg/d) over three weeks in adults with idiopathic pulmonary fibrosis; completed in 2019 and reported in Justice et al., 2019.

  • Future research area — Comparator senolytics: Whether Fisetin (Yousefzadeh et al., 2018) or other flavonoids are more potent or safer than Quercetin as the second component is an open question, with several head-to-head trials at planning stage.

  • Future research area — Senescent-cell biomarkers: Standardization of human senescent-cell biomarkers, including p16INK4a expression and tissue-specific markers, is required to determine which patients benefit and how to dose; the field currently lacks an agreed assay.

  • Future research area — Long-term safety: Multi-year follow-up of intermittent senolytic dosing has not been reported; whether repeated cycles cause cumulative tissue or immune changes is unknown.

  • Future research area — Negative findings and counterevidence: Some preclinical models have failed to reproduce healthspan benefits with D+Q; published null results and controlled blinded trials will be essential to confirm or contradict the early signals.

  • Future research area — Combination with metabolic interventions: Whether D+Q complements, conflicts, or duplicates the effects of other longevity interventions (Rapamycin, Harrison et al., 2009; Metformin, caloric restriction) is largely unexplored.

Conclusion

The Dasatinib & Quercetin senolytic combination represents one of the first translatable strategies aimed at the cellular senescence theory of aging. Preclinical evidence in animal models is broad, showing improvements in healthspan, frailty, and tissue function, while early human pilot evidence in lung-scarring and kidney-related conditions has shown reductions in senescent-cell markers and modest functional signals, without randomized controlled confirmation.

The principal risks stem from the Dasatinib component — fluid around the lungs, suppression of blood-cell production, increased bleeding tendency, heart-rhythm changes, and meaningful drug interactions. Intermittent “hit-and-run” dosing is designed to reduce cumulative exposure, but has not been characterized over years of repeated cycling. Quercetin’s contribution to the human effect remains debated given its limited bioavailability.

For longevity-oriented adults, the case is built on a rich preclinical foundation and a thin but growing human evidence base, much of which originates from the same research group that holds related patents and financial interests in senolytic development — a structural feature of the evidence base that bears on its interpretation. Use outside a registered trial is informal and off-label. The state of the evidence remains preclinically rich and clinically early.

Top - Benefits - Risks - Protocol